For General Information, page-1997

”Out of the running are Selecta’s own gene therapy programs, including SEL-302, an AAV gene therapy in a phase 1/2 trial in combination with ImmTOR for the treatment of an inherited disorder called methylmalonic acidemia.”

itsa: Looks like gene therapy studies are being pulled.
If the FDA insists that Sarepta give them the data at the end of this year Re E51 & 3 other DMD drugs. Which the FDA approved 4 yrs ago on the improviser that Sarepta produce more data showing efficacy .

If the FDA pull the drugs off the market( data failure)
All eyes will turn to ANP $$